The drug composition includes (I) the binding of at least one biologically acceptable nanoparticle with (II) at least one carrier containing at least one pharmaceutical compound to manage an object requiring such pharmaceutical compound, wherein at least one biologically acceptable nanoparticle binds to at least one biologically acceptable nanoparticle Carriers containing drug compounds can improve the effectiveness of related compounds. The maximum size of bioactive nanoparticles is usually between 4 and 500 nanometers, with a surface loading value of at least 10 MV (； 12410 MV. 124；). The carrier is goneAny surface stabilizer It is used to manage the composition of a drug compound in an object requiring the drug, in which at least one biologically bearable nano particle and at least one carrier containing at least one drug compound are respectively managed in an object requiring the drug compound, Usually between five minutes and about 72 hours. Claim 4: the pharmaceutical composition in the third requirement, in which the nanoparticles are selected from one lipid nanoparticles, namely protein nanoparticles,One polymer based nanoparticle, one copolymer based nanoparticle, one carbon based nanoparticle and one viral nanoparticle.Composición farmacéutica que comprende la combinación de (i) al menos una nanopartícula biocompatible y de (ii) al menos un portador que comprende al menos un compuesto farmacéutico, para administrar a un sujeto que necesita de tal compuesto farmacéutico, en donde la combinación de la al menos una nanopartícula biocompatible y del al menos un portador que comprende los compuestos farmacéuticos potencia la eficacia de los compuestos de interés. La dimensión más larga de la nanopartícula biocompatible está típicamente entre aproximadamente 4 y aproximadamente 500 nm y su valor de carga en superficie absoluto es de al menos 10 mV (10 mV). El portador carece, además, de cualquier agente estéricamente estabilizante de superficie. Composición par
